NATCOPHARM

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

** Shares of India's Natco Pharma NATP.NS drop 16.5% to 1017 rupees, marking their biggest intraday loss since debut

** The drugmaker's Q3 consol net profit fell 37.5% y/y, while rev dropped 37.4% y/y

** Stock sees steepest fall since June 5, 2024, set for fifth straight session of losses, if current trend holds

** NATP stock has lost ~27% so far in 2025

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• DIVIDEND 1.5 RUPEES PER SHARE

• DEC-QUARTER CONSOL NET PROFIT 1.33 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.75 BILLION RUPEES

Source text: [ID:]

Further company coverage: NATP.NS

(([email protected];;))

Feb 10 (Reuters) - Lupin Ltd LUPN.NS:

• LUPIN LTD - CO AND NATCO RECEIVE U.S. FDA APPROVAL FOR BOSENTAN TABLETS

Source text: ID:nBSEb28kSJ

Further company coverage: LUPN.NS

(([email protected];;))

Jan 30 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - ANNOUNCES APPROVAL OF ANDA FOR EVEROLIMUS TABLETS

• NATCO PHARMA - BRECKENRIDGE PHARMACEUTICAL TO LAUNCH PRODUCT IMMEDIATELY IN US

Source text: ID:nBSESdMF

Further company coverage: NATP.NS

(([email protected];;))

Jan 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• GETS TAX PENALTY DEMAND ORDER OF 3.8 MILLION RUPEES

Source text: ID:nNSE6CRw55

Further company coverage: NATP.NS

(([email protected];;))

Nov 27 (Reuters) - Natco Pharma Ltd NATP.NS:

• SELLS LAND FOR 1.16 BILLION RUPEES

Source text: ID:nBSE3654XR

Further company coverage: NATP.NS

(([email protected];))

Nov 21 (Reuters) - Natco Pharma Ltd NATP.NS:

• SUBMITS ANDA FOR RISDIPLAM FOR ORAL SOLUTION

• SUBMITTED ANDA WITH US FDA FOR GENERIC VERSION OF EVRYSDI (RISDIPLAM)

• EXPECTS TO BE ELIGIBLE FOR 180 DAYS OF SHARED MARKETING EXCLUSIVITY

Source text: ID:nBSE3BWpw7

Further company coverage: NATP.NS

(([email protected];;))

Nov 20 (Reuters) - Natco Pharma Ltd NATP.NS:

• SOLD INVESTMENT HELD IN ISCA, INC FOR $2.1 MILLION

Source text: ID:nBSE9X7x6J

Further company coverage: NATP.NS

(([email protected];))

Nov 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA SEPT-QUARTER CONSOL NET PROFIT 6.77 BILLION RUPEES

• NATCO PHARMA SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 13.71 BILLION RUPEES

• NATCO PHARMA - DIVIDEND OF 1.5 RUPEESPER SHARE

Source text: [ID:]

Further company coverage: NATP.NS

(([email protected];))

Oct 7 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - MYLAN PHARMA, NOVO NORDISK SETTLE U.S. PATENT LITIGATION OVER GENERIC OZEMPIC

Source text for Eikon: [ID:]

Further company coverage: NATP.NS

(([email protected];))

Sept 4 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA (CANADA) INC. ANNOUNCES US$ 8 MILLION INVESTMENT IN EGENESIS, INC.

Source text for Eikon: ID:nBSE8sm9WY

Further company coverage: NATP.NS

(([email protected];))

** Shares of Natco Pharma NATP.NS up 4.3%; top gainer on pharma index .NIPHARM, which is up 1%

** Co on Thursday said it filed new drug application to U.S. Food & Drug Administration for generic version of Tabrecta tablets

** Drug used to treat lung cancer had sales of $126 mln in U.S in 2023, co said

** NATP up 92% YTD, second biggest gainer among 20 stocks in pharma index, which is up 37%

(Reporting by Sethuraman NR in Bengaluru)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Aug 29 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - SUBMISSION OF ANDA WITH FDA FOR GENERIC VERSION OF TABRECTA

• NATCO PHARMA - SUBMISSION OF ABBREVATED NEW DRUG APPLICATION (ANDA)

Further company coverage: NATP.NS

(([email protected];))

** Shares of Marksans Pharma MARK.NS up 9.4% at 205.4 rupees, its steepest gain since July 24

** Pharmaceutical formulations maker's Q1 consol net profit grew ~30%, rev up 18%

** Shares see busiest day in about 3 weeks, with over 3.2 mln shares traded

** Stock up 28% YTD, vs an 81% and 9% rise in peers Natco Pharma NATP.NS and Mankind Pharma MNKI.NS, respectively

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Shares of Natco Pharma Ltd NATP.NS rise as much as 6.9% to a record high of 1,539.70 rupees

** Drugmaker's Q1 profit jumps 60%, driven by robust exports formulation business

** NATP's Q1 rev up ~20%, while expenses fall 8%

** Stock top gainer on Nifty Pharma index .NIPHARM

** Over 2.9 mln shares traded, 3x the 30-day avg volume

** Analysts tracking stock rate it "buy" on avg - LSEG data

** Stock up 84% YTD, top gainer on Nifty Pharma index

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of India's Natco Pharma NATP.NS up 2.5% after a near 7% jump earlier in the session

** Drugmaker's Q4 consol net profit climbed 40% y/y while rev rose ~19% y/y

** Trading vols 5.7x 30-day avg

** YTD, NATP has gained ~30% after climbing more than 44% in 2023

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

April 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• FRESENIUS KABI USA, LLC AND FRESENIUS KABI DEUTSCHLAND GMBH HAVE FILED A COMPLAINT AGAINST NATCO PHARMA USA LLC

• COMPLAINT AGAINST CO RELATING TO MARKETING OF DASH PHARMACEUTICALS DIAZEPAM INJECTION PREFILLED SYRINGE IN UNITED STATES

• FRESENIUS HAS NOT YET EFFECTUATED SERVICE OF COMPLAINT WHICH IS REQUIRED TO COMMENCE LAWSUIT

• NATCO PHARMA INTENDS TO DEFEND MATTER ACCORDINGLY

Further company coverage: NATP.NS

(([email protected];))

** Shares of Natco Pharma NATP.NS fall as much as 2.2% before trimming some losses to trade 1.4% lower at 986 rupees

** Drug maker says it received warning letter from US FDA after inspection at co's Kothur manufacturing facility

** Co does not believe warning letter impact disruption of supplies or existing revenues from the facility, but says it is likely to cause delay in pending product approvals

** Shares of co down 4.3% last month, snapping three straight months of gains

** Trading vol is 2.2x the 30-day daily avg, highest in more than a month

** NATP's trading volume in March qtr was highest since qtr-ended Dec., 2010

** Avg rating of the 10 analysts is "buy" and median PT is 866 rupees, ~12% lower than current price - LSEG data

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected] ;))

** Shares of Natco Pharma NATP.NS rise as much as 17.6% to 1,043.8 rupees; highest levels since Aug. 13, 2021

** NATP last up 16.4%

** Drug maker raises FY24 PAT guidance to over 12 bln rupees ($144.5 mln) from earlier 10-12 bln rupees

** Stock rallying since co reported a more-than-three-fold jump in Dec-qtr consol net profit on Feb. 14

** NATP set for best one-day rise since Oct. 4, 2017, if gains hold

** NATP top pct gainer on the Nifty Pharma index .NIPHARM, which is up 2%

** Trading vol is 16x the 30-day daily avg, highest since Dec. 7, 2011

** Avg rating of the 11 analysts is "hold" and median PT is 795 rupees, ~22% lower than current price - LSEG data

** Stock rose 44.5% in 2023, after losing for two consecutive years

($1 = 83.0225 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected] ;))

** Shares of Natco Pharma NATP.NS up 4.1% at 891.65 rupees, their highest since Sept. 2023

** Drug maker reported a more than three-fold jump in Dec-qtr consol net profit

** Stock top pct gainer on Nifty pharma index .NIPHARM which is down 1.2%

** Avg rating of analysts on NATP at "hold;" median PT is 795 rupees - LSEG data

** Stock up ~45% in 2023 after falling for two straight years

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Jan 17 (Reuters) - Natco Pharma Ltd NATP.NS:

• INVESTS AROUND $2 MILLION IN CELLOGEN THERAPEUTICS

Further company coverage: NATP.NS

(([email protected];))

Dec 21 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA LTD- CO NAMED AS A DEFENDANT IN AN ANTITRUST LAWSUIT IN US BY LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY

• NATCO PHARMA LTD- ALL CLAIMS AGAINST COMPANY IN LITIGATION HAVE NOW BEEN DISMISSED

Source text for Eikon: ID:nBSEc7VbJ0

Further company coverage: NATP.NS

(([email protected];))

Dec 7 (Reuters) - Natco Pharma Ltd NATP.NS:

• OPERATIONS AT CO'S FACTORY AT MANALI INDUSTRIAL AREA, CHENNAI, TAMIL NADU HAVE BEEN TEMPORARILY DISRUPTED DUE TO CYCLONE

• NO MATERIAL IMPACT ON THE FINANCIAL POSITION OR SALES OF THE COMPANY

Source text for Eikon: ID:nNSE2RGzcD

Further company coverage: NATP.NS

(([email protected];;))

** Shares of Indian drug maker Cipla CIPL.NS rise as much as 2.4% to a record 1,283.55 rupees

** Stock has added 9% since reporting strong Q2 results on Oct. 30 and has since gained in 11 of the 16 sessions

** Pharma index .NIPHARM up 1% Wednesday, led by gains in CIPL, Natco Pharma NATP.NS, GlaxoSmithKline PharmaGLAX.NS, Sanofi SANO.NS among others

** CIPL up 18% YTD, underperforming 28% gains in pharma index

(Reporting by Sethuraman NR)

(([email protected]; (+91 9945291420); Reuters Messaging: [email protected]))

Nov 2 (Reuters) - Natco Pharma Ltd NATP.NS:

• SUCCESSFULLY COMPLETED USFDA INSPECTION OF CO’S COMPLIANCE TO PHARMACOVIGILANCE REQUIREMENTS

• USFDA INSPECTION COMPLETED TO PHARMACOVIGILANCE REQUIREMENTS WITH ZERO OBSERVATIONS

Further company coverage: NATP.NS

(([email protected];))

Oct 19 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA LTD - COMPLETION OF AN INSPECTION BY USFDA FOR ITS PHARMA DIVISION LOCATED IN KOTHUR HYDERABAD, INDIA

• NATCO PHARMA LTD - FACILITY RECEIVED EIGHT (8) OBSERVATIONS

Source text for Eikon: ID:nNSE4jjFPg

Further company coverage: NATP.NS

(([email protected];))

Sept 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• CELGENE CORP, BRISTOL MYERS SQUIBB, BRECKENRIDGE PHARMACEUTICAL INC. AND CO NAMED DEFENDANTS IN AN ANTITRUST LAWSUIT IN US

• LAWSUIT BY LOUISIANA HEALTH SERVICE & INDEMNITY COMPANY D/B/A BLUE CROSS AND BLUE SHIELD OF LOSISIANA AND HMO LOUISIANA INC

• LAWSUIT REGARDING POMALIDOMIDE

• NATCO BELIEVES THIS MATTER IS WITHOUT MERIT

Source text for Eikon: ID:nBSEbkLBNG

Further company coverage: NATP.NS

(([email protected];))

By Brendan Pierson

Sept 6 (Reuters) - Bristol Myers Squibb BMY.N has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it should have faced generic competition.

In a complaint filed on Tuesday in Manhattan federal court, Blue Cross Blue Shield of Louisiana said the company violated U.S. antitrust law and had caused purchasers of the drug to overpay "by many hundreds of millions, if not billions, of dollars."

The health insurer brought the claim on behalf of a proposed nationwide class of entities that paid for Pomalyst since October 2020, when it claimed generic versions of the multiple myeloma treatment would have launched if not for the illegal scheme.

It is seeking three times the amount of the alleged overcharge, which is permitted under the federal Sherman Act antitrust law.

A spokesperson for Bristol Myers did not immediately respond to a request for comment.

Pomalyst is a top seller for Bristol Myers, bringing in nearly $3.5 billion out of $46.16 billion of its total revenue last year. The company in July forecast sales of the drug to fall this year, however, as more patients receive it for free through a patient assistance program.

The drug was developed by Celgene, a company acquired by Bristol Myers in 2019. Tuesday's lawsuit claims that Celgene fraudulently obtained multiple patents on it based on information that was already in the public domain, a fact it concealed from the U.S. Patent and Trademark Office while it was applying for the patents.

The company then used those patents to file "sham lawsuits" against generic drugmakers to prevent them from launching their own versions of Pomalyst, the lawsuit said.

Bristol Myers eventually reached settlements with several generic companies including Teva Pharmaceutical Industries TEVA.TA, Aurobindo Pharma ARBN.NS, Breckeridge Pharmaceutical and Natco Pharma NATP.N under which they agreed delay the launch of generics until 2026.

Blue Cross Blue Shield of Louisiana said that while the exact terms of the agreements were "cloaked under an effort at absolute secrecy," the economic incentives for the companies suggest they must have been "large, unjustified" payments in exchange for not launching generics, which can be illegal.

The generic companies, which are also named as defendants in the lawsuit, did not immediately respond to requests for comment.

(Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi and Bill Berkrot)

(([email protected]; 332-219-1345 (desk); 646-306-0235 (cell);))

Aug 30 (Reuters) - Natco Pharma Ltd NATP.NS:

• INVESTS $2 MILLION IN ISCA INC

Source text for Eikon: ID:nBSEbFRNPY

Further company coverage: NATP.NS

(([email protected];))